Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Recordati continues clinical development of BPH Rx

Feb. 13, 1998

Controlled-release oxybutynin to be marketed in Europe by Synthelabo

Feb. 2, 1998

Synaptic develops selective human alpha1A-receptor antagonists

Feb. 2, 1998

RTX enters phase II for urge incontinence

Jan. 27, 1998

FDA accepts RenaGel NDA for filing

Jan. 22, 1998

New urinary incontinence product from Biomatrix cleared for clinical trials

Jan. 12, 1998

Synaptic, Merck & Co. extend BPH research agreement

Jan. 5, 1998

Cephalon describes new indolocarbazoles for prostate disorders

Dec. 30, 1997

NDA filed for extended-release Ditropan formulation

Dec. 29, 1997

Bladder efficacy demonstrated for KATP channel opener

Dec. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...